UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

Journal of clinical oncology, 2009-06, Vol.27 (16), p.2705-2711

2009

Volltextzugriff (PDF)

Clinical Trials of Arsenic Trioxide in Hematologic and Solid Tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies

The oncologist (Dayton, Ohio), 2001-04, Vol.6 (S2), p.22-28

Murgo, Anthony J.

2001

Volltextzugriff (PDF)

Drug development in oncology: classical cytotoxics and molecularly targeted agents

British journal of clinical pharmacology, 2006-07, Vol.62 (1), p.15-26

2006

Volltextzugriff (PDF)

Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura

Clinical cancer research, 2006-10, Vol.12 (19), p.5777-5785

2006

Volltextzugriff (PDF)

Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies

Clinical cancer research, 2007-09, Vol.13 (18), p.5411-5417

2007

Volltextzugriff (PDF)

Designing Phase 0 Cancer Clinical Trials

Clinical cancer research, 2008-06, Vol.14 (12), p.3675-3682

2008

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Journal of clinical oncology, 2008-02, Vol.26 (4), p.570-576

2008

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Journal of clinical oncology, 2008-02, Vol.26 (4), p.563-569

2008

Volltextzugriff (PDF)

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Cancer research (Chicago, Ill.), 2011-09, Vol.71 (17), p.5626-5634

2011

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms

Journal of clinical oncology, 2002-10, Vol.20 (19), p.4074-4082

2002

Volltextzugriff (PDF)

Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma

Clinical cancer research, 2006-10, Vol.12 (19), p.5809-5816

2006

Volltextzugriff (PDF)

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Clinical cancer research, 2011-08, Vol.17 (15), p.5123-5131

2011

Volltextzugriff (PDF)

Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013

Cancer, 2014-10, Vol.120 (19), p.3025-3032

2014

Volltextzugriff (PDF)

Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas

Cancer biology & therapy, 2009-11, Vol.8 (21), p.2004-2009

2009

Volltextzugriff (PDF)

Compressing drug development timelines in oncology using phase '0' trials

Nature reviews. Cancer, 2007-02, Vol.7 (2), p.131-139

2007

Volltextzugriff (PDF)

Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

Clinical cancer research, 2010-02, Vol.16 (3), p.1073-1084

2010

Volltextzugriff (PDF)

Improving the Quality of Abstract Reporting for Phase I Cancer Trials

Clinical cancer research, 2008-03, Vol.14 (6), p.1782-1787

2008

Volltextzugriff (PDF)

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

European journal of cancer (1990), 2010-01, Vol.46 (2), p.340-347

2010

Volltextzugriff (PDF)

Phase I and Correlative Study of Combination Bryostatin 1 and Vincristine in Relapsed B-Cell Malignancies

Clinical cancer research, 2003-12, Vol.9 (16), p.5929-5935

2003

Volltextzugriff (PDF)

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

Blood, 2008-01, Vol.111 (2), p.566-573

2008

Volltextzugriff (PDF)

Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study

Gynecologic oncology, 2004-04, Vol.93 (1), p.144-148

2004

Volltextzugriff (PDF)

Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice

Molecular interventions, 2007-12, Vol.7 (6), p.325-334

2007

Volltextzugriff (PDF)

Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials

Clinical cancer research, 2013-05, Vol.19 (10), p.2637-2645

2013

Volltextzugriff (PDF)

Effects of α1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-Hydroxystaurosporine

Clinical cancer research, 2004-10, Vol.10 (20), p.6840-6846

2004

Volltextzugriff (PDF)

1 – 25 von 104

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(94)
Mit Volltextzugriff
(91)

Publikationsform

Artikel
(102)
Buchkapitel
(2)

Sprache

Englisch
(104)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(75)
Science & Technology
(68)
Life Sciences & Biomedicine
(66)
Oncology
(52)
Biological And Medical Sciences
(45)
Male
(44)
Medical Sciences
(44)
Female
(43)
Middle Aged
(37)
Adult
(34)
Pharmacology. Drug Treatments
(33)
Aged
(32)
Antineoplastic Agents
(29)
Neoplasms - Drug Therapy
(29)
Tumors
(22)
Antineoplastic Agents - Pharmacokinetics
(20)
Antineoplastic Agents - Administration & Dosage
(17)
Dose-Response Relationship, Drug
(17)
Maximum Tolerated Dose
(16)
Antineoplastic Agents - Adverse Effects
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

Clinical Trials of Arsenic Trioxide in Hematologic and Solid Tumors: Overview of the National Cancer Institute Cooperative Research and Development Studies

Drug development in oncology: classical cytotoxics and molecularly targeted agents

Phase I Study of Decitabine-Mediated Gene Expression in Patients with Cancers Involving the Lungs, Esophagus, or Pleura

Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies

Designing Phase 0 Cancer Clinical Trials

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group

Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas

Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients With Advanced Neoplasms

Phase I Study of Bryostatin 1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent (Non-Hodgkin's) Lymphoma

Multihistology, Target-Driven Pilot Trial of Oral Topotecan as an Inhibitor of Hypoxia-Inducible Factor-1α in Advanced Solid Tumors

Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013

Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas

Compressing drug development timelines in oncology using phase '0' trials

Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

Improving the Quality of Abstract Reporting for Phase I Cancer Trials

Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies

Phase I and Correlative Study of Combination Bryostatin 1 and Vincristine in Relapsed B-Cell Malignancies

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma

Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study

Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice

Assessment of Audit Methodologies for Bias Evaluation of Tumor Progression in Oncology Clinical Trials

Effects of α1-Acid Glycoprotein on the Clinical Pharmacokinetics of 7-Hydroxystaurosporine

Suchergebnisse filtern